NutraMax, Inc.
https://www.nutramaxlabs.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NutraMax, Inc.
ASCO: AstraZeneca Achieves Eye-Catching Solid Tumor Results With 'Armored' CAR-T
Solid tumor CAR-T may succeed AZD7003 where many others have failed as the firm builds its cell therapy pipeline.
Akari, Peak Bio Hatch Merger Plan To Survive Together
Deal snapshot: Akari, which has stayed afloat through small financings in recent years, and Peak Bio, after going public via the SPAC route in 2022, will merge as equals and then prioritize their pipeline.
Finance Watch: FogPharma’s Platform Against Unreachable Targets Attracts $145m Series E
Private Company Edition: FogPharma raised $145m for its clinical-stage drug and earlier programs after bringing on former Johnson & Johnson R&D head Mathai Mammen as CEO last year. Also, BlossomHill closed a $100m series B round and Kenai emerged with $82m in series A cash.
Amgen Doubles Down On AI, Genomic Investments In R&D
David Reese, chief technology officer and former EVP of R&D, and newly appointed EVP of R&D Jay Bradner spoke with Scrip about how Amgen is pairing artificial intelligence with genomics plus data milestones in 2024.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Nutramax Laboratories Consumer Care, Inc.
- Nutramax Laboratories Veterinary Sciences, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice